| WB | 1/2002-1/4000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/25 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Tyrosine-protein kinase HCK, Hematopoietic cell kinase, Hemopoietic cell kinase, p59-HCK/p60-HCK, p59Hck, p61Hck, HCK |
| Entrez GeneID | 3055 |
| WB Predicted band size | 59.6kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This HCK antibody is generated from a mouse immunized with a recombinant protein of human HCK. |
+ +
以下是假设的关于HCK抗体的参考文献示例(非真实文献，仅供示例参考)：
---
1. **文献名称**：*Development of a Monoclonal Antibody Targeting HCK for Leukemia Research*
**作者**：Smith J. et al.
**摘要**：研究团队开发了一种高特异性的抗HCK单克隆抗体，通过免疫印迹和流式细胞术验证其在白血病细胞中的结合能力，证明其可用于检测HCK在急性髓系白血病(AML)中的异常激活。
2. **文献名称**：*HCK Inhibition via Neutralizing Antibody Suppresses Tumor Growth in Solid Cancers*
**作者**：Johnson R. et al.
**摘要**：研究发现HCK在实体瘤(如乳腺癌)的肿瘤微环境中通过调控巨噬细胞活性促进免疫逃逸。使用特异性中和抗体阻断HCK功能后，显著抑制了小鼠模型中肿瘤的生长和转移。
3. **文献名称**：*Structural Insights into HCK-Antibody Interaction for Targeted Therapy*
**作者**：Zhang L. et al.
**摘要**：通过冷冻电镜技术解析了HCK激酶结构域与其治疗性抗体的复合物结构，揭示了抗体通过结合HCK的SH3域抑制其激酶活性的分子机制，为优化抗体药物提供理论依据。
4. **文献名称**：*HCK Antibody-Based Biomarker Panel for Chronic Inflammation Diagnosis*
**作者**：Lee S. et al.
**摘要**：基于抗HCK抗体的多标志物检测体系，成功区分了类风湿性关节炎患者的炎症程度，表明HCK表达水平与疾病活动性相关，为临床诊断提供了新工具。
---
注：以上内容为虚构示例，实际文献需通过学术数据库(如PubMed、Web of Science)检索。
HCK (hematopoietic cell kinase) is a member of the Src family of non-receptor tyrosine kinases, primarily expressed in hematopoietic cells such as neutrophils, macrophages, and B lymphocytes. It plays a critical role in regulating cellular signaling pathways involved in immune responses, inflammation, and hematopoiesis. Structurally, HCK contains SH3 and SH2 domains that mediate protein-protein interactions and a catalytic kinase domain responsible for phosphorylating downstream targets. Its activity is tightly controlled by phosphorylation at specific regulatory sites (e.g., Tyr416 activation and Tyr527 inhibitory sites).
HCK signaling is activated by various stimuli, including cytokines, growth factors, and integrin engagement. It participates in phagocytosis, cell migration, and cytokine production by modulating pathways like PI3K/AKT, MAPK, and NF-κB. Dysregulation of HCK has been implicated in pathological conditions, particularly hematologic malignancies. Overactivation of HCK is observed in certain leukemias and lymphomas, where it promotes cell proliferation and survival. Additionally, HCK contributes to chronic inflammatory diseases by enhancing inflammatory mediator release.
HCK-specific antibodies are vital tools for studying its expression, phosphorylation status, and interactions in disease models. They enable applications such as Western blotting, immunohistochemistry, and flow cytometry, aiding in both basic research and therapeutic development. Recent efforts also explore HCK inhibitors as potential treatments for cancers and autoimmune disorders, highlighting its clinical relevance.
×
